Thiazolidinediones and liver toxicity

Diabetes and Metabolism

Volumn 27, Issue 3, 2001, Pages 305-313

  Scheen, A J ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Hepatitis; Liver toxicity; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; GLUCOSE; INSULIN; LIVER ENZYME; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOCOPHEROL; TROGLITAZONE;

ADULT; AGED; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MARKETING; GLUCOSE BLOOD LEVEL; HEPATITIS; HUMAN; INSULIN RESISTANCE; LIVER TOXICITY; MALE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LIVER; LIVER FAILURE; THIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0034930107     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Insulin resistance and antidiabetic drugs
2. Oral antidiabetic agents: A guide to selection
3. Management of the obese diabetic patient
4. Insulin resistance and atherosclerosis
5. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: Achievements and future developments
6. Mechanisms and clinical effects of thiazolidinediones
7. Thiazolidinediones
8. Thiazolidinediones: A new class of antidiabetic drugs
9. Les thiazolidinediones
10. Thiazolidinediones: An update
11. Thiazolidinediones in the treatment of insulin resistance and type Il diabetes
12. PPAR-gamma adipogenic regulator and thiazolidinedione receptor
13. Troglitazone
14. Troglitazone: An antidiabetic agent
15. Troglitazone: Review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus
16. Troglitazone. A review of its use in the management of type 2 diabetes mellitus
17. Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes
18. Antidiabetic drugs present and future: Will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
19. Troglitazone and related compounds. Therapeutic potential beyond diabetes
20. Rosiglitazone
21. Pioglitazone
22. Hepatic dysfunction associated with troglitazone
23. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
24. Drug-induced hepatic disorders: Incidence, management and avoidance
25. Drug-induced hepatotoxicity
26. Liver disease and diabetes mellitus
27. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss
28. The pathology of diabetic hepatitis
29. Criteria of drug-induced liver disorders: Report of an international consensus meeting
30. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents
31. Thiazolidinediones for type 2 diabetes
32. Thiazolidinedione hepatotoxicity: A class effect?
33. Hepatotoxicity with glitazones: Is it a class effect?
34. Diabetes drug withdrawn after reports of hepatic events
35. Troglitazone. Is it all over?
36. The rise and fall of troglitazone
37. Liver damage warnings for troglitazone
38. Call to ban troglitazone in US
39. Troglitazone ban loses support
40. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
41. Troglitazone-induced hepatic failure leading to liver transplantation
42. An autopsy case of troglitazone-induced fulminant hepatitis
43. Fatal hepatotoxicity associated with troglitazone
44. Troglitazone-associated hepatic failure
45. Severe hepatotoxicity associated with troglitazone
46. Troglitazone-associated hepatic failure
47. A Japanese case of liver dysfunction after 19 months of troglitazone treatment
48. Rapid-onset subfulminant liver failure associated with troglitazone
49. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: A case report with autopsy examination
50. Hepatic injury due to troglitazone
51. Troglitazone-induced fulminant hepatic failure
52. Severe but reversible hepatitis induced by troglitazone
53. Troglitazone-associated hepatic failure
54. Troglitazone-associated hepatotoxicity treated successfully with steroids
55. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
56. Liver dysfunction associated with troglitazone (Noscal)
57. Liver dysfunction due to troglitazone
58. Clinical effect and side effect of troglitazone
59. Learning to use troglitazone
60. A novel antidiabetic drug, troglitazone - Reason for hope and Concern
61. Hepatic injury due to drugs and toxins
62. Troglitazone has a scavenging effect on reactive oxygen species
63. Use of hepatocyte cultures for the study of hepatotoxicity compounds
64. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures
65. Toxicity of troglitazone in cultured rat hepatocytes
66. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease
67. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrinogenic and proinflammatory actions in hepatic stellate cells
68. Rosiglitazone and pioglitazone: Two new thiazolidinediones
69. Rosiglitazone
70. Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review
71. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week randomized, placebo controlled study
72. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
73. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus
74. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
75. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus
76. Rosiglitazone is not associated with hepatotoxicity
77. Rosiglitazone liver safety update
78. Troglitazone prevents fatty changes of the liver in obese diabetic rats
79. Hepatic failure in a patient taking rosiglitazone
80. Hepatocellular injury in a patient receiving rosiglitazone. A case report
81. Rosiglitazone and hepatic failure
82. Rosiglitazone and liver failure
83. New drug overview. Pioglitazone hydrochloride
84. Pioglitazone: From discovery to clinical practice
85. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes
86. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in the treatment of patients with type 2 diabetes mellitus: A randomized, placebo-controlled study
87. Pioglitazone hydrochloride in combination with metformin in the treatment of patients with type 2 diabetes mellitus: A randomized placebo-controlled study
88. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials